Brokerages expect that Illumina, Inc. (NASDAQ:ILMN) will report sales of $825.83 million for the current quarter, according to Zacks. Seven analysts have provided estimates for Illumina’s earnings, with the lowest sales estimate coming in at $775.00 million and the highest estimate coming in at $838.99 million. Illumina posted sales of $714.00 million in the same quarter last year, which suggests a positive year-over-year growth rate of 15.7%. The business is expected to report its next earnings report on Tuesday, October 23rd.

According to Zacks, analysts expect that Illumina will report full-year sales of $3.31 billion for the current year, with estimates ranging from $3.23 billion to $3.38 billion. For the next financial year, analysts forecast that the business will post sales of $3.75 billion per share, with estimates ranging from $3.54 billion to $4.03 billion. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that that provide coverage for Illumina.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Monday, July 30th. The life sciences company reported $1.43 earnings per share for the quarter, beating analysts’ consensus estimates of $1.11 by $0.32. The business had revenue of $830.00 million for the quarter, compared to the consensus estimate of $786.88 million. Illumina had a net margin of 20.88% and a return on equity of 26.64%. Illumina’s revenue for the quarter was up 25.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.82 EPS.

A number of research analysts have recently weighed in on the stock. BidaskClub upgraded shares of Illumina from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 1st. Cowen raised their price target on shares of Illumina from $315.00 to $400.00 and gave the company a “positive” rating in a report on Thursday, September 6th. Argus set a $372.00 target price on shares of Illumina and gave the stock a “buy” rating in a report on Friday, August 10th. Morgan Stanley upgraded shares of Illumina from an “underweight” rating to an “equal weight” rating and lifted their target price for the stock from $210.00 to $320.00 in a report on Tuesday, August 7th. Finally, ValuEngine upgraded shares of Illumina from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 31st. Five analysts have rated the stock with a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $308.25.

In other news, SVP Mostafa Ronaghi sold 7,500 shares of the business’s stock in a transaction dated Tuesday, July 10th. The shares were sold at an average price of $288.89, for a total transaction of $2,166,675.00. Following the transaction, the senior vice president now owns 78,496 shares in the company, valued at approximately $22,676,709.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Francis A. Desouza sold 2,100 shares of the business’s stock in a transaction dated Monday, July 2nd. The stock was sold at an average price of $276.14, for a total transaction of $579,894.00. Following the transaction, the chief executive officer now owns 83,282 shares in the company, valued at approximately $22,997,491.48. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 45,837 shares of company stock worth $14,939,513. Insiders own 0.54% of the company’s stock.

Large investors have recently bought and sold shares of the company. Kaizen Advisory LLC increased its holdings in shares of Illumina by 161.0% during the 2nd quarter. Kaizen Advisory LLC now owns 368 shares of the life sciences company’s stock worth $103,000 after purchasing an additional 227 shares during the period. Moneta Group Investment Advisors LLC increased its holdings in shares of Illumina by 2,670.0% during the 2nd quarter. Moneta Group Investment Advisors LLC now owns 9,695 shares of the life sciences company’s stock worth $107,000 after purchasing an additional 9,345 shares during the period. Sun Life Financial INC increased its holdings in shares of Illumina by 152.5% during the 2nd quarter. Sun Life Financial INC now owns 399 shares of the life sciences company’s stock worth $111,000 after purchasing an additional 241 shares during the period. Migdal Insurance & Financial Holdings Ltd. increased its holdings in shares of Illumina by 3,192.3% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 428 shares of the life sciences company’s stock worth $120,000 after purchasing an additional 415 shares during the period. Finally, Hall Laurie J Trustee boosted its position in shares of Illumina by 189.5% during the 2nd quarter. Hall Laurie J Trustee now owns 550 shares of the life sciences company’s stock valued at $154,000 after acquiring an additional 360 shares in the last quarter. Institutional investors own 89.81% of the company’s stock.

Shares of Illumina stock traded up $3.66 during midday trading on Thursday, reaching $350.88. 516,700 shares of the company’s stock traded hands, compared to its average volume of 878,647. The company has a market capitalization of $51.91 billion, a P/E ratio of 87.39, a P/E/G ratio of 2.93 and a beta of 0.97. The company has a current ratio of 2.74, a quick ratio of 2.44 and a debt-to-equity ratio of 0.22. Illumina has a 52 week low of $196.00 and a 52 week high of $357.93.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Featured Story: Do You Need a Fiduciary?

Get a free copy of the Zacks research report on Illumina (ILMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.